Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.
Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 uninfected patients | Other | Patient with negative PCR result |
|
| non-hospitalized COVID-19 infected patients | Other | Patient with positive PCR result who does not require hospitalization for COVID-19 |
|
| hospitalized COVID-19 infected patients | Other | Patient with positive PCR who require hospitalization for COVID-19 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Baseline and during hospitalization blood samples | Other | Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :
|
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients. | The CD3 + T lymphocyte cell populations (CD4 + ILT2 + and CD8 + ILT2 +) will be compared between the groups of patients | 1 month |
| Comparison of the expression of circulating soluble HLA-G, between the groups of patients. | Blood levels of soluble HLA-G and plasma microvesicles with expression of HLA-G will be compared between the groups of patients. | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| 1 month survival | Vital status collected 1 month post inclusion for all the patients | 1 month |
| Assessment of the severity of the disease according to the isoform of HLA-G | Comparison of the isoforms (alleles) of HLA-G regarding the severity of the disease for the infected patients. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Olivier BRUGIERE, PhD | Hopital Foch | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Foch hospital | Suresnes | 92151 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C074807 | BaseLine dental cement |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline blood sample | Other | Blood sample will be performed at the inclusion visit only |
|
| 1 month |
| Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G. | The expression of the BSG cell receptor induced by HLA-G will be compared between COVID19 patients and uninfected patients. | 1 day |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |